Predictors of infliximab efficacy in patients with severe attack of ulcerative colitis
Aim of investigation. Biological therapy by monoclonal antibodies against tumor necrosis factor (infliximab) allows to avoid colectomy at steroid-resistant severe attack of ulcerative colitis. High cost of such treatment and risk of adverse events related to it requires definition of strict indicati...
Saved in:
Main Authors: | A. O. Golovenko, I. L. Khalif, O. V. Golovenko, V. V. Veselov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Gastro LLC
2013-10-01
|
Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
Subjects: | |
Online Access: | https://www.gastro-j.ru/jour/article/view/1233 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of mesalazine at ulcerative colitis with nutritional failure
by: A. V. Korolyov, et al.
Published: (2015-03-01) -
Features of development and progression of colorectal cancer on a background of ulcerative colitis
by: I. L. Khalif, et al.
Published: (2012-02-01) -
Results of formation of primary and secondary smallintestinal reservoirs at ulcerative colitis
by: V. N. Kashnikov, et al.
Published: (2014-12-01) -
Mesalazine use tactics in the ulcerative colitis patients
by: A. V. Korolev, et al.
Published: (2013-03-01) -
Prevalence of Erosive-ulcerative Lesions of the Stomach and Helicobacter Pylori Infection in Patients with Ulcerative Colitis
by: N. A. Ponkratova, et al.
Published: (2019-06-01)